Anaemia Clinical Trial
Official title:
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia associated with chronic kidney disease who are not taking rhEPO and are not undergoing dialysis. The range of Hgb values for study eligibility is 8.5-11.0 g/dL. Eligible subjects will be randomized in equal proportions to receive once daily (QD) placebo or GSK1278863 0.5 mg, 2 mg or 5 mg in a double-blind fashion.
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group,
multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in
approximately 68 subjects with anemia associated with chronic kidney disease who are not
taking rhEPO and are not undergoing dialysis. The study consists of a screening phase of up
to 2 weeks, a 4-week treatment phase and a 2-week follow-up phase. The range of Hgb values
for study eligibility is 8.5-11.0 g/dL. Eligible subjects will be randomized in equal
proportions to receive once daily (QD) placebo or GSK1278863 0.5 mg, 2 mg or 5 mg in a
double-blind fashion. Study treatment will be stopped if Hgb values fall outside of the range
pre-specified in the protocol.
This study aims to estimate the relationship between dose of GSK1278863 and Hgb response for
correcting anemia in non-dialysis subjects with CKD who are not taking rhEPO (NDD). In
addition, the study will characterize the effect of GSK1278863 on various
pharmacokinetic/pharmacodynamic (PK/PD) markers, and will investigate the safety and
tolerability of GSK1278863.
An early interim analysis of the Hgb data is planned after approximately 20 subjects from
cohort 1 have completed 3 weeks of treatment. Depending upon the interim findings, a second
cohort of subjects may be added to investigate an additional GSK1278863 dose arm. Recruitment
to the first cohort will continue during the interim analysis.
A second interim analysis is planned after approximately 48 subjects from cohort 1 have
completed 4 weeks treatment. The purpose of this interim is three-fold, to investigate
whether a second cohort of subjects may be added, to facilitate early development of
dose-response and PK/PD statistical models, and to generate interim results to facilitate
design and dosing decisions for the next trial.
Subject completion is defined as completion of all study phases including the follow-up
phase.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05682326 -
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
|
Phase 3 | |
| Completed |
NCT03400033 -
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
|
Phase 3 | |
| Completed |
NCT02879305 -
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
|
Phase 3 | |
| Completed |
NCT02876835 -
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
|
Phase 3 | |
| Terminated |
NCT02801162 -
Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard
|
N/A | |
| Completed |
NCT02288637 -
Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product
|
N/A | |
| Completed |
NCT00276224 -
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
|
N/A | |
| Completed |
NCT00857077 -
Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana
|
N/A | |
| Completed |
NCT06080555 -
Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia
|
Phase 1 | |
| Completed |
NCT01977573 -
A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
|
Phase 2 | |
| Completed |
NCT02243306 -
Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
|
Phase 1 | |
| Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
| Completed |
NCT00140517 -
Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance
|
N/A | |
| Completed |
NCT03239522 -
Absorption and Elimination of Radiolabeled Daprodustat
|
Phase 1 | |
| Completed |
NCT01376232 -
Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)
|
Phase 1 | |
| Completed |
NCT02019719 -
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT02969655 -
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02637102 -
The UK CAVIAR Study
|
||
| Completed |
NCT01454752 -
Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition
|
N/A | |
| Completed |
NCT01136850 -
Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea
|
Phase 3 |